Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lysogene initiates phase II/III study of its AAV/rh.10-SGSH gene therapy

Jan. 10, 2019

Demser approved in Japan to improve catecholamine excess secretion in patients with pheochromocytoma

Jan. 9, 2019

Japan first to approve Evenity for osteoporosis

Jan. 9, 2019

Homology Medicines nominates in vivo gene editing development candidate for PKU

Jan. 8, 2019

Phase I results reported for oral ferroportin inhibitor VIT-2763

Jan. 7, 2019

Positive topline results presented from first cohort of phase I/II study of DTX-401

Jan. 7, 2019

Horizon Pharma and HemoShear Therapeutics to jointly discover therapeutics for gout

Jan. 4, 2019

Arcturus Therapeutics nominates ARCT-810 as development candidate for OTC deficiency

Jan. 2, 2019

Amgen develops anti-GIPR antibody

Dec. 31, 2018

FDA approves sNDA to expand the age range for Ravicti oral liquid to include newborns

Dec. 28, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...